Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

The summary for the Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional): The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the companion FOAs listed above.
Federal Grant Title: Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-23-016
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.393, 93.394, 93.395, 93.396, 93.399
CFDA Descriptions: Information not provided
Current Application Deadline: November 17th, 2023
Original Application Deadline: November 17th, 2023
Posted Date: December 22nd, 2022
Creation Date: December 22nd, 2022
Archive Date: December 23rd, 2023
Total Program Funding:
Maximum Federal Grant Award: $600,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: December 22nd, 2022
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement
https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-016.html
Grant Announcement Contact
NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer ...
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Cli...
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...
Pilot Studies in Pancreatic Cancer
Cancer Prevention Research Small Grant Program
Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health
NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required...
NIH HEAL Initiative: Coordinated Approaches to Pain Care in Health Care Systems (UG3/UH3 -...
HAZMAT Training at DOE Nuclear Weapons Complex (UH4 Clinical Trial Not Allowed)
Single Source: NINDS Exploratory Clinical Trials (U01 Clinical Trial Required)
Safety and Efficacy of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com